[Contribution of microCT structural imaging to preclinical evaluation of @entity157 chemotherapeutics on orthotopic graft in ACI XXXX ].

@entity901 @entity23974 @entity5 @entity2857 @entity158 @entity35 @entity157 @entity136
Animal experimentation is a prerequisite for preclinical evaluation of treatments such as chemotherapy. It's strictly regulated with the purpose of reducing the number of experimental animal as well as their @entity158 . Small animal imaging should provide a painless longitudinal follow up of @entity5 progression on a single animal. The aim of the study is to validate small animal imaging by microscanner ( scan) in longitudinal follow up of a @entity157 ( @entity157 ) and to demonstrate its interest for in vivo evaluation of @entity5 response to different therapeutics. An @entity157 model achieved by orthotopic graft of the MH3924A cell line in ACI @entity35 was followed using a Imtek/Siemens microscanner ( scan) with contrast agents (Fenestra(  ) LC/VC). The procedures giving the optimal enhancement of the liver as well as a reliable determination of @entity5 volumes by  scan were validated. Three protocols for therapeutic assessment through  scan longitudinal follow up were performed. Each consisted in three groups testing a chemotherapy ( @entity136 , @entity136 - @entity901 or @entity2857 ) versus two control groups (placebo and @entity23974 ). Comparison was done on @entity5 volumes, median and actual survivals. There was a significant correlation between @entity5 volumes measured by  scan and autopsy. Treatment by @entity2857 , at the contrary of @entity136 alone or with @entity901 , resulted in a significant reduction in @entity5 volumes and prolongation of actuarial survival. These results are consistent with available clinical data for these diverse therapeutics. In conclusion, small animal imaging with  scan is a non-invasive, reliable, and reproducible method for preclinical evaluation of antitumor agents.
